Synopsis

Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking!

Synopsis

• The history of epigenetics – from first wave to present day 
• Benefits of RNA modifying enzymes as a target 
• Precise combination therapeutics in cancer (including epigenetics) for patients in the future 

Synopsis

• Introduction to RNA modifications, the role of METTL3 and the m6A modification on selected mRNA species
• Overview of our drug discovery efforts to identify potent and selective inhibitors of METTL3
• Characterisation of potent, selective, bioavailable inhibitors of METTL3 in biochemical, biophysical and cellular assays
• Exploration of utility of METTL3 inhibitors in hematological and solid tumour cell lines
• Demonstration of in vivo activity of METTL3 inhibitors in hematological and solid tumour models

Synopsis

• Introduction to Omni-C, a single assay for SNP detection, SV mapping and
  chromatin 3-D landscape characterization
• Insights into drug response by capturing the 3-D gene regulatory landscape
• Chromatin topology improves cancer genome characterization
• Enhancing bio-marker discoveries with genome topology

Synopsis

• Cancer immunophenotypes and immune escape mechanisms – how to address resistance to immune checkpoint therapy
• Immunomodulatory features of epigenetic drugs – rationale selection of combinations, dose, and schedule
• Case studies: i) Broad-spectrum HDAC inhibitor resminostat in combination with opsonizing antibodies in haematological cancer; ii) Class I HDAC inhibitor domatinostat in combination with checkpoint blockade – translation of preclinical findings into the clinic

Synopsis

• Inhibition of LSD1 by irreversible binding to the FAD cofactor
• Iadademstat for treatment of AML and SCLC
• Increased of neuronal plasticity and improvement of cognitive and behavioral functions by treatment with vafidemstat
• Modulation of LSD1 activity as a personalized medicine strategy in CNS disease.

Synopsis

Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking!

Synopsis

• The design and biological validation of compounds able to simultaneously hit two epigenetic targets will be discussed with their effects in cancer diseases, in comparison with the single-target inhibitors.

Synopsis

• Streamlining and reduce workflow time using automated ChIP-seq with the Covaris Adaptive Focused Acoustics (AFA)
• Evaluation of the AFA technology in a range of epitopes, including H3K4me3, H3K27me3, H3K27ac, RNA Pol-II, CTCF, and HNF4A in different cell lines.
• How to utilize AFA-based ChIP-seq processes for rapid epigenetic drug screening and clinical diagnostics

Synopsis

• Improving treatment of ovarian cancer is a major clinical unmet need.
• Epigenetic adaptation is a driver of drug resistance in ovarian cancer.
• Potential of histone methyltransferases to overcome drug resistance.
• Modulation of the immune microenvironment by histone methyltransferases.

Synopsis

• Can HDAC inhibitors really work as a monotherapy?
• Clinical trial implications of combination therapies

Synopsis

• The journey to personalized medicine and the role epigenetics will play 
• How to design a drug development pipeline for precision medicine 
• The future of personalised medicine – a pipe dream or legitimate goal? 

Synopsis

Automated online speed networking – randomized matches made automatically based on profile – 5 rounds of 3 mins – to help people “accidentally meet”.

Synopsis

• Overcoming the obstacles of toxicity regardless of target 
• Techniques for monitoring toxicity and balancing this with efficacy 
• Debating the dangers of off-target effects versus on-target effects 

Synopsis

• Designing a successful clinical trial – balancing efficacy and safety
• Patient cohorts based on a diagnostic tool that identifies patients with specific EZH2 mutations
• Future implications, plans and the move towards precision medicine in oncology

Synopsis

• Epigenetic regulation and BET system in CVD/T2DM
• Mechanism of Apabetalone
• Highlights of Pre-clinical and Clinical Data

Synopsis

• SMARCA4 is mutationally-inactivated in subsets of lung cancer leading to a dependency on the paralog helicase, SMARCA2
• The discovery and development of selective SMARCA2 inhibitors would be essential for therapeutically targeting SMARCA4-mutant lung cancers
• In vitro characterization and demonstration of in vivo activity of potent and selective degraders of SMARCA2

Synopsis

• Specificity and properties of a compound in relation to clinical application
• Creating an oral drug and a dosing schedule that works
• Virus activation vs HDAC inhibitors

Synopsis

Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking!

Synopsis

• Optimal combination agents to use with BET bromodomain inhibitors in the clinic
• Patient populations that can benefit from combinatorial therapies with ZEN-3694
• Biomarkers of response of ZEN-3694 + enzalutamide in mCRPC patients

Synopsis

• Utilizing epigenetics in combination with immunotherapies to further bolster the immune response
• Building a differentiated oncology portfolio based on standalone epigenetic (mono)therapies
• Imagining the future of epigenetic therapies in oncology and beyond